Hematology Patient Protection During the COVID-19 Pandemic in Italy: A Nationwide Nursing Survey.

COVID-19 Coronavirus Hematology Infection control Infection spread Nursing Patient Protection Patient safety SARS-CoV-2

Journal

Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512

Informations de publication

Date de publication:
2021
Historique:
received: 21 09 2020
accepted: 11 12 2020
entrez: 25 1 2021
pubmed: 26 1 2021
medline: 26 1 2021
Statut: epublish

Résumé

Italy has been one of the first European countries hit by the COVID-19 pandemic, with many patients dying from severe respiratory issues, especially frail subjects. Hematology patients are generally thought to be at high risk of developing severe COVID-19-associated complications. The aim of this work was to describe the infection control measures adopted in Italian hematology settings to protect patients and health-care professionals. On behalf of the Nursing Campus in Hematology Group, a nationwide nursing survey was conducted. Questionnaire items included general information, infection control measures, patient and health-care professional protection, information management, and participants' opinion on critical issues. Data have been analyzed by center location (Northern, Central, or Southern Italy) and by patient age (adult vs pediatric). Forty-four Italian hematology centers participated, representing 52.4% of those invited. Patients underwent nasopharyngeal swabs (93.2%) generally the day before admission (43.2%), though less frequently in Southern centers (p = 0.0377). Visitor restrictions were implemented in all centers: 65.9% barred all visitors, while 25.0% allowed visitors only for patients with specific conditions, especially in Central Italy. Deficiency of personal protective equipment, including masks (45.5%) and gloves (22.7%), was reported, although the nurses' opinion was that the emergency was nevertheless well managed to protect patients and professionals. Almost all health-care institutions (97.7%) provided recommendations on emergency management. No significant differences were found between adult and pediatric centers in terms of infection prevention and control. Low variability in patient protection strategies was observed, meaning that national recommendations were effective. However, some critical issues emerged regarding the management of infected health-care professionals and their contacts.

Sections du résumé

BACKGROUND BACKGROUND
Italy has been one of the first European countries hit by the COVID-19 pandemic, with many patients dying from severe respiratory issues, especially frail subjects. Hematology patients are generally thought to be at high risk of developing severe COVID-19-associated complications. The aim of this work was to describe the infection control measures adopted in Italian hematology settings to protect patients and health-care professionals.
MATERIALS AND METHODS METHODS
On behalf of the Nursing Campus in Hematology Group, a nationwide nursing survey was conducted. Questionnaire items included general information, infection control measures, patient and health-care professional protection, information management, and participants' opinion on critical issues. Data have been analyzed by center location (Northern, Central, or Southern Italy) and by patient age (adult vs pediatric).
RESULTS RESULTS
Forty-four Italian hematology centers participated, representing 52.4% of those invited. Patients underwent nasopharyngeal swabs (93.2%) generally the day before admission (43.2%), though less frequently in Southern centers (p = 0.0377). Visitor restrictions were implemented in all centers: 65.9% barred all visitors, while 25.0% allowed visitors only for patients with specific conditions, especially in Central Italy. Deficiency of personal protective equipment, including masks (45.5%) and gloves (22.7%), was reported, although the nurses' opinion was that the emergency was nevertheless well managed to protect patients and professionals. Almost all health-care institutions (97.7%) provided recommendations on emergency management. No significant differences were found between adult and pediatric centers in terms of infection prevention and control.
DISCUSSION CONCLUSIONS
Low variability in patient protection strategies was observed, meaning that national recommendations were effective. However, some critical issues emerged regarding the management of infected health-care professionals and their contacts.

Identifiants

pubmed: 33489050
doi: 10.4084/MJHID.2021.011
pii: mjhid-13-1-e2021011
pmc: PMC7813272
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e2021011

Déclaration de conflit d'intérêts

Competing interests: The authors declare no conflict of Interest.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
J Med Internet Res. 2020 Nov 13;22(11):e22205
pubmed: 33048825
Bone Marrow Transplant. 2020 Nov;55(11):2071-2076
pubmed: 32404975
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Wound Manag Prev. 2020 Oct;66(10):12-16
pubmed: 33048827
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Leukemia. 2020 Aug;34(8):2000-2011
pubmed: 32444866
Front Med. 2020 Apr;14(2):117-125
pubmed: 32318975
Br J Haematol. 2020 Jul;190(1):e3-e5
pubmed: 32368790
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
Curr Oncol Rep. 2020 May 8;22(5):53
pubmed: 32385672
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Haematol. 2020 Aug;7(8):e601-e612
pubmed: 32563283
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Front Oncol. 2020 Jul 22;10:1279
pubmed: 32903324
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
Blood. 2020 Aug 6;136(6):763-766
pubmed: 32559271
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Biol Blood Marrow Transplant. 2020 Jun;26(6):1043-1049
pubmed: 32305359
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Leukemia. 2020 Aug;34(8):2260-2261
pubmed: 32555369
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856

Auteurs

Stefano Botti (S)

Hematology Unit, Azienda USL-IRCCS Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy.

Nicola Serra (N)

Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, via S. Pansini 80131 Naples, Italy.

Fausto Castagnetti (F)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, via G. Massarenti 9, 40138 Bologna, Italy.

Sabina Chiaretti (S)

Heamatology, Department of Precision and Translational Medicine, Sapienza University, piazzale A. Moro 5, 00185 Rome, Italy.

Nicola Mordini (N)

Hematology Division, AO S. Croce e Carle, via M. Coppino 26, 12100 Cuneo, Italy.

Gianpaolo Gargiulo (G)

Hematology and Hematopoietic Stem Cell Transplantation Centre, Federico II University Hospital of Naples, via Pansini 80131 Naples, Italy.

Laura Orlando (L)

Hemato-Oncology Unit, Istituto Oncologico della Svizzera Italiana (IOSI), via A. Gallino 12, 6500 Bellinzona, Switzerland.

Classifications MeSH